PPARG and large cell carcinoma: Despite the above, enthusiasm forthis approach should be tempered by work showing that thePPAR-γ ligands rosiglitazone, ciglitazone, and PGJ2 werefound to stimulate PPAR-γ transactivation in lungadenocarcinoma cell lines in vitro,but little to no effects were noted in squamous cell or large cell carcinomas suggestingthat their anticancer properties might not be shared by all lung tumors, orthat important PPAR-γ-independent pathways are at play [108, 110].